Physician profile
Anila Kanna
NPI 1538515200
$2,999.23
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $74.24 · 2021: $390 · 2022: $656 · 2023: $721 · 2024: $1,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $838.51 | 2022-2024 | Briviact, Nayzilam, Fintepla |
| Sk Life Science, INC. | $655.00 | 2021-2024 | |
| Neurelis, INC. | $410.79 | 2020-2024 | Valtoco |
| Alexion Pharmaceuticals, INC. | $194.22 | 2021-2024 | Ultomiris |
| Grt US Holding, INC. | $123.33 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $116.42 | 2021-2023 | Austedo |
| Biogen, INC. | $109.82 | 2021-2024 | Skyclarys |
| Octapharma USA, INC. | $97.58 | 2024 | Panzyga |
| Genentech USA, INC. | $70.63 | 2022-2023 | Ocrevus |
| Jazz Pharmaceuticals INC. | $62.89 | 2023-2024 | |
| Lundbeck LLC | $40.54 | 2022-2023 | Vyepti |
| Argenx US, INC. | $30.28 | 2022 | |
| Amgen INC. | $26.70 | 2024 | Uplizna |
| Acorda Therapeutics, INC | $25.68 | 2023 | Inbrija |
| Abbvie INC. | $23.80 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pyros Pharmaceuticals, INC. | $21.43 | 2024 | Vigpoder |
| Ptc Therapeutics, INC. | $21.13 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $20.72 | 2022 | |
| Immedica Pharma US, INC. | $17.74 | 2024 | |
| Janssen Pharmaceuticals, INC | $17.10 | 2022 | |
| Kyowa Kirin, INC. | $16.01 | 2021 | |
| Horizon Therapeutics Plc | $15.73 | 2023 | Uplizna |
| Aquestive Therapeutics, INC. | $14.60 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $14.56 | 2021 | |
| Biomarin Pharmaceutical INC. | $14.02 | 2023 | Brineura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anila Kanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.